{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:38:43Z","timestamp":1790746723295,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Serrated adenocarcinoma (SAC) is more invasive, has worse outcomes than conventional colorectal carcinoma (CRC), and is characterized by frequent resistance to anti-epidermal growth factor receptor (EGFR) and overexpression of fascin1, a key protein in actin bundling that plays a causative role in tumor invasion and is overexpressed in different cancer types with poor prognosis. In silico screening of 9591 compounds, including 2037 approved by the Food and Drug Administration (FDA), was performed, and selected compounds were analyzed for their fascin1 binding affinity by differential scanning fluorescence. The results were compared with migrastatin as a typical fascin1 inhibitor. In silico screening and differential scanning fluorescence yielded the FDA-approved antidepressant imipramine as the most evident potential fascin1 blocker. Biophysical and different in vitro actin-bundling assays confirm this activity. Subsequent assays investigating lamellipodia formation and migration and invasion of colorectal cancer cells in vitro using 3D human tissue demonstrated anti-fascin1 and anti-invasive activities of imipramine. Furthermore, expression profiling suggests the activity of imipramine on the actin cytoskeleton. Moreover, in vivo studies using a zebrafish invasion model showed that imipramine is tolerated, its anti-invasive and antimetastatic activities are dose-dependent, and it is associated with both constitutive and induced fascin1 expression. This is the first study that demonstrates an antitumoral role of imipramine as a fascin1 inhibitor and constitutes a foundation for a molecular targeted therapy for SAC and other fascin1-overexpressing tumors.<\/jats:p>","DOI":"10.1038\/s12276-020-0389-x","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T04:02:43Z","timestamp":1582171363000},"page":"281-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells"],"prefix":"10.1038","volume":"52","author":[{"given":"Bego\u00f1a","family":"Alburquerque-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Bernab\u00e9-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoro-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Bernab\u00e9-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila Campioni","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ruiz Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando F.","family":"L\u00f3pez-Calder\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Cayuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuula","family":"Salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"P\u00e9rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-3044","authenticated-orcid":false,"given":"Pablo","family":"Conesa-Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"389_CR1","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/nature08978","volume":"464","author":"L Chen","year":"2010","unstructured":"Chen, L., Yang, S., Jakoncic, J., Zhang, J. J. & Huang, X. Y. Migrastatin analogues target fascin to block tumour metastasis. Nature 464, 1062\u20131066 (2010).","journal-title":"Nature"},{"key":"389_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4161\/cib.3.3.11556","volume":"3","author":"LM Machesky","year":"2010","unstructured":"Machesky, L. M. & Li, A. Fascin: Invasive filopodia promoting metastasis. Commun. Integr. Biol. 3, 263\u2013270 (2010).","journal-title":"Commun. Integr. Biol."},{"key":"389_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ijc.27674","volume":"132","author":"P Conesa-Zamora","year":"2013","unstructured":"Conesa-Zamora, P. et al. Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma. Int. J. Cancer 132, 297\u2013307 (2013).","journal-title":"Int. J. Cancer"},{"key":"389_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-52","volume":"11","author":"VY Tan","year":"2013","unstructured":"Tan, V. Y., Lewis, S. J., Adams, J. C. & Martin, R. M. Association of Fascin1-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 11, 52 (2013).","journal-title":"BMC Med."},{"key":"389_CR5","doi-asserted-by":"publisher","first-page":"74736","DOI":"10.18632\/oncotarget.20360","volume":"8","author":"PC Rodrigues","year":"2017","unstructured":"Rodrigues, P. C. et al. Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma. Oncotarget 8, 74736\u201374754 (2017).","journal-title":"Oncotarget"},{"key":"389_CR6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.humpath.2010.04.002","volume":"41","author":"J Garc\u00eda-Solano","year":"2010","unstructured":"Garc\u00eda-Solano, J. et al. Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. Hum. Pathol. 41, 1359\u20131368 (2010).","journal-title":"Hum. Pathol."},{"key":"389_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/j.1365-2559.2011.04043.x","volume":"59","author":"J Garc\u00eda-Solano","year":"2011","unstructured":"Garc\u00eda-Solano, J., Conesa-Zamora, P., Trujillo-Santos, J., M\u00e4kinen, M. J. & P\u00e9rez-Guillermo, M. Tumour budding and other prognostic pathological features at invasive margins in serrated colorectal adenocarcinoma: a comparative study with conventional carcinoma. Histopathology 59, 1046\u20131056 (2011).","journal-title":"Histopathology"},{"key":"389_CR8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.humpath.2011.08.020","volume":"43","author":"J Garc\u00eda-Solano","year":"2012","unstructured":"Garc\u00eda-Solano, J. et al. Immunohistochemical expression profile of \u03b2-catenin, E-cadherin, P-cadherin, laminin-5\u03b32 chain, and SMAD4 in colorectal serrated adenocarcinoma. Hum. Pathol. 43, 1094\u20131102 (2012).","journal-title":"Hum. Pathol."},{"key":"389_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/j.1365-2559.2011.03821.x","volume":"58","author":"K Stefanius","year":"2011","unstructured":"Stefanius, K. et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology 58, 679\u2013692 (2011).","journal-title":"Histopathology"},{"key":"389_CR10","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/ijc.27454","volume":"131","author":"J Garc\u00eda-Solano","year":"2012","unstructured":"Garc\u00eda-Solano, J. et al. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. Int. J. Cancer 131, 1790\u20131799 (2012).","journal-title":"Int. J. Cancer"},{"key":"389_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.molonc.2016.03.006","volume":"10","author":"S Han","year":"2016","unstructured":"Han, S. et al. Improving fascin inhibitors to block tumor cell migration and metastasis. Mol. Oncol. 10, 966\u2013980 (2016).","journal-title":"Mol. Oncol."},{"key":"389_CR12","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nature03197","volume":"432","author":"BK Shoichet","year":"2004","unstructured":"Shoichet, B. K. Virtual screening of chemical libraries. Nature 432, 862\u2013865 (2004).","journal-title":"Nature"},{"key":"389_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1021\/ci2005274","volume":"52","author":"MP Sanders","year":"2012","unstructured":"Sanders, M. P. et al. Comparative analysis of pharmacophore screening tools. J. Chem. Inf. Model. 52, 1607\u20131620 (2012).","journal-title":"J. Chem. Inf. Model."},{"key":"389_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1021\/ci049885e","volume":"45","author":"G Wolber","year":"2005","unstructured":"Wolber, G. & Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 45, 160\u2013169 (2005).","journal-title":"J. Chem. Inf. Model."},{"key":"389_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1021\/ci900419k","volume":"50","author":"H Geppert","year":"2010","unstructured":"Geppert, H., Vogt, M. & Bajorath, J. Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation. J. Chem. Inf. Model. 50, 205\u2013216 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"389_CR16","doi-asserted-by":"publisher","first-page":"30087","DOI":"10.1074\/jbc.M111.251439","volume":"286","author":"S Jansen","year":"2011","unstructured":"Jansen, S. et al. Mechanism of actin filament bundling by fascin. J. Biol. Chem. 286, 30087\u201330096 (2011).","journal-title":"J. Biol. Chem."},{"issue":"1737","key":"389_CR17","doi-asserted-by":"publisher","first-page":"20160482","DOI":"10.1098\/rstb.2016.0482","volume":"373","author":"Tuula Salo","year":"2017","unstructured":"Salo, T. et al. Organotypic three-dimensional assays based on human leiomyoma-derived matrices. Philos. Trans. R. Soc. Lond. B Biol. Sci. 373, 20160482 (2018). https:\/\/doi.org\/10.1098\/rstb.2016.0482.","journal-title":"Philosophical Transactions of the Royal Society B: Biological Sciences"},{"key":"389_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-4939-7595-2_19","volume":"1731","author":"P \u00c5str\u00f6m","year":"2018","unstructured":"\u00c5str\u00f6m, P., Heljasvaara, R., Nyberg, P., Al-Samadi, A. & Salo, T. Human tumor tissue-based 3D in vitro invasion assays. Methods Mol. Biol. 1731, 213\u2013221 (2018).","journal-title":"Methods Mol. Biol."},{"key":"389_CR19","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/onc.2010.593","volume":"30","author":"B Jelassi","year":"2011","unstructured":"Jelassi, B. et al. P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene 30, 2108\u20132122 (2011).","journal-title":"Oncogene"},{"key":"389_CR20","doi-asserted-by":"publisher","first-page":"E8234","DOI":"10.1073\/pnas.1618389114","volume":"114","author":"R Fior","year":"2017","unstructured":"Fior, R. et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc. Natl Acad. Sci. USA 114, E8234\u2013E8243 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR21","doi-asserted-by":"publisher","first-page":"11326","DOI":"10.1021\/ja048779q","volume":"126","author":"C Gaul","year":"2004","unstructured":"Gaul, C. et al. The migrastatin family: discovery of potent cell migration inhibitors by chemical synthesis. J. Am. Chem. Soc. 126, 11326\u201311337 (2004).","journal-title":"J. Am. Chem. Soc."},{"key":"389_CR22","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/cam4.746","volume":"5","author":"CQ Wang","year":"2016","unstructured":"Wang, C. Q. et al. Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. Cancer Med. 5, 1983\u20131988 (2016).","journal-title":"Cancer Med."},{"key":"389_CR23","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1078-0432.CCR-05-2281","volume":"12","author":"SM Rodr\u00edguez-Pinilla","year":"2006","unstructured":"Rodr\u00edguez-Pinilla, S. M. et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res. 12, 1533\u20131539 (2006).","journal-title":"Clin. Cancer Res."},{"key":"389_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/jclinpath-2013-201698","volume":"67","author":"AK Esnakula","year":"2014","unstructured":"Esnakula, A. K. et al. Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women. J. Clin. Pathol. 67, 153\u2013160 (2014).","journal-title":"J. Clin. Pathol."},{"key":"389_CR25","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/2159-8290.CD-13-0183","volume":"3","author":"NS Jahchan","year":"2013","unstructured":"Jahchan, N. S. et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3, 1364\u20131377 (2013).","journal-title":"Cancer Discov."},{"key":"389_CR26","unstructured":"Sauer, T. & Lang, U. E. Is imipramine helpful in the treatment of cancer? A case presentation and discussion of possible clinical implications. Biomed. J. Sci. Tech. Res. 4, 4194\u20134195 (2018)."},{"key":"389_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.bjc.6605996","volume":"104","author":"AJ Walker","year":"2011","unstructured":"Walker, A. J., Card, T., Bates, T. E. & Muir, K. Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br. J. Cancer 104, 193\u2013197 (2011).","journal-title":"Br. J. Cancer"},{"key":"389_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1242\/dmm.008243","volume":"6","author":"R Kraft","year":"2013","unstructured":"Kraft, R. et al. A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions. Dis. Model. Mech. 6, 217\u2013235 (2013).","journal-title":"Dis. Model. Mech."},{"key":"389_CR29","doi-asserted-by":"publisher","first-page":"127ra36","DOI":"10.1126\/scitranslmed.3003016","volume":"4","author":"JM Munson","year":"2012","unstructured":"Munson, J. M. et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci. Transl. Med. 4, 127ra36 (2012).","journal-title":"Sci. Transl. Med."},{"key":"389_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/17460441.2017.1297416","volume":"12","author":"HK Brown","year":"2017","unstructured":"Brown, H. K., Schiavone, K., Tazzyman, S., Heymann, D. & Chico, T. J. Zebrafish xenograft models of cancer and metastasis for drug discovery. Expert Opin. Drug Discov. 12, 379\u2013389 (2017).","journal-title":"Expert Opin. Drug Discov."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s12276-020-0389-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s12276-020-0389-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s12276-020-0389-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:11:42Z","timestamp":1684602702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-0389-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1038\/s12276-020-0389-x","relation":{},"ISSN":["1226-3613","2092-6413"],"issn-type":[{"value":"1226-3613","type":"print"},{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"15 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}